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Abstract
Background—In the Denosumab and Teriparatide Administration (DATA) study, we showed 
that denosumab fully inhibits teriparatide-induced bone resorption while allowing for continued 
teriparatide-induced bone formation, resulting in larger increases in hip and spine bone mineral 
density (BMD) than with either drug alone. We aimed to assess whether administration of 
denosumab with high dose teriparatide would stimulate larger increases in bone mass than those 
observed in the DATA study.
Methods—DATA-HD was an open-label, randomised, controlled phase 4 trial done at 
Massachusetts General Hospital. Eligible women were postmenopausal women (at least 36 months 
since last menses or since hysterectomy with a follicle-stimulating hormone concentration of ≥40 
U/L) with osteoporosis. Participants were randomly assigned (1:1) to receive teriparatide 20 μg 
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(standard dose) or 40 μg (high dose) daily via subcutaneous injection for 9 months. At 3 months, 
both groups were started on denosumab 60 mg every 6 months via subcutaneous injection for 12 
months. Areal BMD (aBMD) was measured at 0, 3, 9, and 15 months. Treatment was given open 
label, but outcome assessors were masked. The primary endpoint was percentage change from 
baseline in spine areal BMD (aBMD) at 15 months. Women who completed at least one study visit 
after baseline were included in the modified intention-to-treat analysis. Safety was assessed in all 
randomly assigned participants. This study is registered with ClinicalTrials.gov, number 
NCT02176382.
Findings—Between Oct 15, 2014, and June 10, 2016, 269 women were assessed for eligibility. 
76 participants were randomly assigned to 20 μg teriparatide (n=39) or 40 μg teriparatide (n=37), 
of whom 69 completed at least one post-baseline visit. At 15 months, mean spine aBMD had 
increased to a significantly greater extent in the 40 μg group (17·5% [SD 6·0] increase) than the 20 
μg group (9·5% [3·2]; difference 8·1%, 95% CI 5·5 to 10·6, p<0·0001). Mean femoral neck aBMD 
had also increased to a greater extent in the 40 μg group (6·8% [SD 4·1] increase) than the 20 μg 
group (4·3% [3·7]; difference 2·5%, 0·5 to 4·5, p=0·04), as did mean total hip aBMD (40 μg group, 
6·1% [3·4] increase; 20 μg group, 3·9% [2·9] increase; difference 2·2%, 0·6 to 3·8, p<0·0001). 30 
(77%) of 39 participants in the 20 μg group and 29 (78%) of 37 participants in the 40 μg group had 
an adverse event, and seven (18%) and two (5%) patients had serious adverse events. The most 
frequent adverse events were joint pain (15 [38%]), muscle cramp (15 [38%]), and fatigue (12 
[31%]) in the 20 μg group group and fatigue (14 [38%]), nausea (16 [43%]), and joint pain (17 
[46%]) in the 40 μg group. No deaths were reported.
Interpretation—Combined treatment with teriparatide 40 μg and denosumab increases spine and 
hip BMD more than standard combination therapy. This large and rapid increase in bone mass 
suggest that this high dose regimen might provide a method of restoring skeletal integrity in 
patients with osteoporosis.
Introduction
Although the number of osteoporosis therapies has expanded substantially over the past two 
decades, available antiresorptive and anabolic medications result in only modest increases in 
bone mineral density (BMD) and modest reductions in non-vertebral fracture rates.1–10 
Since the global population is ageing, osteoporosis remains a considerable health-care 
burden and an urgent need exists to develop new therapeutic regimens that can fully restore 
skeletal integrity. By contrast with many other chronic, age-related diseases, osteoporosis 
remains a disease primarily treated with monotherapy.
Several studies11–14 have investigated the potential efficacy of combining teriparatide or 
related compounds with the most commonly used antiresorptive drugs—the nitrogen-
containing bisphosphonates such as alendronate or zoledronic acid—but this approach has 
not been found to have any advantage compared with monotherapy. Conversely, in the 
Denosumab and Teriparatide Administration (DATA) trial,15–18 we showed that the 
combination of teriparatide and the receptor activator of nuclear factor ͬ-B ligand inhibitor, 
denosumab, increased BMD, improved skeletal microarchitecture, and increased estimated 
bone strength to a greater extent than either drug alone.15–18 In DATA, biochemical markers 
of bone resorption were identically suppressed in patients treated with denosumab alone and 
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in those treated with denosumab plus teriparatide, whereas markers of bone formation were 
suppressed to a greater extent in those treated with denosumab alone than those treated with 
denosumab plus teriparatide, indicating that the efficacy of this combination is likely to be 
due to denosumab’ s ability to fully block the resorptive effects of teriparatide while possibly 
allowing for teriparatide-induced stimulation of modelling-based bone formation (ie, bone 
formation that occurs over bone surfaces not undergoing concomitant bone resorption). On 
the basis of these findings, we aimed to investigate whether combining a more potent 
anabolic stimulus (high dose teriparatide) with denosumab over a short duration would result 
in larger increases in BMD than that with standard dose teriparatide.
Methods
Study design and participants
The Denosumab and High-dose Teriparatide Administration (DATA-HD) study was an 
open-label, phase 4, randomised controlled trial done at Massachusetts General Hospital 
(Boston, MA, USA).
Women aged 45 years or older were recruited through targeted mailings, advertisements, and 
physician referrals. Eligible women were postmenopausal (at least 36 months since last 
menses or since hysterectomy with a follicle-stimulating hormone concentration of ≥40 U/L) 
and had osteoporosis with a high risk of fracture (defined as a BMD T score of ≤−2·5 at the 
spine, hip, or femoral neck; a T score of ≤−2·0 with at least one BMD-independent risk 
factor [ fracture after age 50 years, parental hip fracture after age 50 years, previous 
hyperthyroidism, inability to rise from a chair with arms elevated, or current smoking];19 or 
a T score of ≤−1·0 at the spine, hip, or forearm with a history of ≥1 fragility fractures). 
Women were excluded if they had evidence of hyperparathyroidism, vitamin D deficiency 
(serum level <20 ng/mL), congenital or acquired bone disease, history of malignancy (with 
the exception of non-melanoma skin cancer), history of radiation therapy, significant 
cardiopulmonary, liver, or renal disease, major psychiatric disease, excessive alcohol intake, 
known sensitivity to denosumab or teriparatide, or were planning extensive dental work in 
the 2 months before or following enrolment. Women who had taken oral bisphosphonate or 
denosumab within 6 months before enrolment, oestrogens, selective oestrogen receptor 
modulators, or calcitonin within 3 months before enrolment, oral or parenteral 
glucocorticoids for more than 14 days within 6 months before enrolment, or who had ever 
received strontium or any parenteral bisphosphonate were also excluded. Full exclusion 
criteria are in the appendix (pp 5, 6).
The study protocol was approved by the Partners Healthcare Institutional Review Board. 
Written informed consent was received from all participants before inclusion in the study. 
The study protocol is in the appendix (p 2).
Randomisation and masking
Before randomisation, women were stratified on the basis of age (≥65 years vs or <65 years) 
and previous bisphosphonate use (yes or no). Participants were randomly assigned (1:1) to 
receive teriparatide 20 μg (standard dose) or 40 μg (high dose). Randomisation was done by 
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computer-generated cards provided by our research pharmacy. Within each stratum, the 
randomisation block size varied randomly to minimise the predictability of treatment 
assignments. Participants were aware of treatment assignment, but outcome assessors were 
masked.
Procedures
Eligible participants received teriparatide 20 μg (standard dose) or 40 μg (high dose) daily 
via subcutaneous injection for 9 months (appendix p 1). At 3 months, both groups were 
started on denosumab 60 mg every 6 months via subcutaneous injection for 12 months. 
Thus, between 9 and 15 months participants received denosumab monotherapy. Participants 
received calcium carbonate and vitamin D supplements if needed to achieve a total daily 
intake of 1200 mg elemental calcium and to maintain serum 25-hydroxyvitamin D 
concentrations of at least 20 ng/mL. Adherence to teriparatide was assessed via participant 
diaries. At 15 months, all participants were given the opportunity to participate in an 
extension study that consisted of receiving one dose of intravenous zoledronic acid 5 mg, 
which is ongoing.
Areal BMD (aBMD) of the posterior-anterior lumbar spine, total hip, femoral neck, and the 
distal one-third of the radial shaft was assessed at 0, 3, 9, and 15 months by dual x-ray 
absorptiometry (DXA) using a Hologic QDR 4500A densitometer (Hologic, Waltham, MA, 
USA). All scans of an individual patient were done using the same densitometer. Daily 
quality control assessments were done with a Hologic anthropomorphic spine phantom. The 
SD values for in vivo reproducibility of measurements are 0·005 g/cm2 for the lumbar spine, 
0·006 g/cm2 for the total hip, and 0·007 g/cm2 for the femoral neck. Vertebrae in which 
obvious deformities or focal sclerosis were detected were excluded. Forearm DXA of the 
non-dominant arm was done if there was no history of wrist fracture.
Volumetric BMD (vBMD) of the lumbar spine (L1-L2) and proximal femur was assessed 
using a 16-multidetector-row quantitative CT scanner (Revolution GSI; GE Healthcare, 
Waukesha, WI, USA). vBMD was assessed at 0 and 15 months only. Participants were 
placed supine in the quantitative CT scanner on a calibration phantom (Mindways Software, 
Austin, TX, USA), and helical scanning of the lumbar spine and from the proximal articular 
surface of the femoral head to 1 cm below the lessor trochanter, was done using the 
following parameters: 120 kV, 100 mA (lumbar spine), 120 kV, 200 mA (proximal femur), 
slice thickness 2·5 mm, field of view 500 mm, and table height of 144 mm (2 year 
coefficient of variation ≤2%). We used basic engineering principles to apply a finite element 
analysis to both the spine and hip using VirtuOst software (O.N. Diagnostics, Berkeley, CA, 
USA), as described elsewhere.20 Briefly, the image voxels were converted into cube-shaped 
finite elements and then a compressive force on the spine or a sideways fall at the hip was 
simulated on this finite element model. For the lumbar spine, a thin layer of plastic was 
virtually applied over each endplate through which the vertebral body was loaded to 
simulate failure for a uniform compressive overload. For the hip, a sideways fall was 
simulated with the diaphysis angled at 15° to the ground and 15° of internal rotation. For 
both sites, bone strength was calculated from the resulting non-linear force-deformation 
curves as the force at 1·9% and 4·0% overall deformation of the spine and hip, respectively. 
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This technique enabled the estimation of differences in strength at 15 months compared with 
baseline for the whole bone at the spine and total hip. The software used for the finite 
element analysis of bone strength is approved by the US Food and Drug Administration for 
clinical diagnostic and monitoring purposes and has been validated in multiple clinical 
fracture outcome studies.21–24
Fasting morning blood samples were obtained at 0, 3, 9, and 15 months. All samples, 
including calcium serum concentrations, were assessed 24 h after the last teriparatide dose 
when applicable. Bone formation markers serum type I N-terminal propeptide of type 1 
procollagen (P1NP) and osteocalcin and the bone resorption marker C-terminal telopeptide 
of type 1 collagen (CTX) were measured using the Roche Cobas e411 auto-analyser (Roche 
Diagnostics, Penzberg, Germany). The interassay coefficients of variation for P1NP, 
osteocalcin, and CTX were 4·5, 5·3, and 4·4%, respectively. For each marker, all blood 
samples from a participant were frozen at −80°C and analysed together in the same assay 
run after one freeze-thaw cycle. Biochemical markers of bone turnover were only measured 
in participants who completed all study visits.
Adverse events including bone fractures were documented at each study visit. All serious 
adverse events were reviewed by an independent data and safety monitoring board. Adverse 
events were considered serious if participants were admitted to hospital or there was a 
clinically significant change in medical condition.
Outcomes
The primary endpoint was percentage change from baseline in lumbar spine aBMD at 15 
months, assessed by DXA. Secondary endpoints were the change in total hip, femoral neck, 
and distal radius aBMD, assessed by DXA; vBMD and estimated strength assessed by spine 
and hip quantitative CT; change in distal tibia and distal radius assessed by high resolution 
peripheral quantitative CT (HR-pQCT); and biochemical markers of bone turnover. Change 
in distal tibia and distal radius by HR-pQCT secondary outcomes will be reported elsewhere.
Statistical analysis
To detect a between-group difference in lumbar spine aBMD of 2·5% (ie, the lower limit of 
what is considered clinically important and greater than the least significant change based on 
spine DXA), with 80% power at a two-sided significance level of 5%, a sample size of 35 
participants per group was required, assuming a dropout rate of 14%. Between-group 
differences were assessed using repeated measures ANOVA. The subject level random 
intercept, time, fixed treatment effect, and the interaction between group and time were 
included in the model. The inference of the regression coefficient associated with the 
interaction term (difference in slopes) determined differences between treatment groups. The 
model allowed for the inclusion of all available partial observations for the non-completers. 
The primary endpoint was assessed in the modified intention-to-treat analysis set, which 
included all participants who completed at least one study visit after baseline. Secondary 
endpoints were also assessed in the modified intention-to-treat analysis set, with exception 
of the biochemical markers, which was only assessed in patients who completed the study. 
Safety was assessed in all randomly assigned participants. Quantitative CT spine and hip 
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results were omitted for two participants in the 20 μg group: one patient had a missing 
quantitative CT phantom at the time of the scan and one participant did not wish to have 
quantitative scans done. We did not impute missing data. Between-group differences in 
quantitative CT measures (two measures for each participant) were assessed by Wilcoxon-
Mann-Whitney test after assessment for normality. A p value of 0·05 or less was considered 
to indicate statistical significance. Data are presented as mean (SD) for endpoints with a 
normal distribution and as median (IQR) for endpoints without a normal distribution. For the 
mean percentage change in aBMD by DXA, SEs have been presented in figures rather than 
SDs, as per the reporting conventions for this study area. Statistical analysis was done with 
SAS (version 9.2). This study is registered with ClinicalTrials.gov, number NCT02176382.
Role of the funding source
The funders had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all the data in the study 
and had final responsibility for the decision to submit for publication.
Results
Between Oct 15, 2014, and June 10, 2016, 269 women were assessed for eligibility. 76 
participants were randomly assigned to 20 μg teriparatide (n=39) or 40 μg teriparatide 
(n=37), of whom 69 completed at least one post-baseline visit and were included in this 
analysis (figure 1). Baseline characteristics are shown in table 1. 34 (97%) of 35 women in 
the 20 μg group and 34 (100%) of 34 women in the 40 μg group reported taking at least 85% 
of their daily teriparatide doses. Two women in the 40 μg group reported reducing their 
teriparatide dose to 20 μg daily after 5 months due to nausea. All women in both groups 
received all expected denosumab doses. The final 15 month follow-up visit was completed 
on Sept 27, 2017
At 15 months, aBMD had increased from baseline in both treatment groups at all measured 
sites (figure 2). The mean percentage increase in lumbar spine aBMD was significantly 
higher in the 40 μg group (17·5% [SD 6·0]) than the 20 μg group (9·5% [3·2]; difference 
8·1%, 95% CI 5·5 to 10·6, p<0·0001).
The mean percentage increase in femoral neck aBMD was also significantly higher in the 40 
μg group (6·8% [SD 4·1]) than the 20 μg group (4·3% [3·7]; difference 2·5%, 95% CI 0·5 to 
4·5, p=0·04). Total hip aBMD also increased by 6·1% (3·4) in the 40 μg group compared 
with 3·9% (2·9) in the 20 μg group (difference 2·2%, 95% CI 0·6 to 3·8, p<0·0001). At 9 
months, total hip and femoral neck aBMD had increased by more than 5% and spine aBMD 
increased by around 14% in the 40 μg group. At the distal one-third of the radial shaft, 
aBMD transiently decreased in both groups after 3 months of treatment with teriparatide 
alone, but had increased to a similar extent by 15 months (difference 0·5%, 95% CI −1·1 to 
2·1, p=0·43).
At 15 months, vBMD increased in both treatment groups with significantly larger increases 
observed in the 40 μg group than in the 20 μg group at all sites (figure 3). Mean spine vBMD 
increased by 32·2% (SD 17·0) in the 40 μg group and 13·3% (18·8) in the 20 μg group 
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(difference 18·2%, 95% CI 10·4 to 26·0, p<0·0001), femoral neck vBMD increased by 5·2% 
(6·0) in the 40 μg group and 1·4% (6·7) in the 20 μg group (difference 3·8%, 0·4 to 7·2, 
p=0·030), and total hip vBMD increased by 6·3% (4·4) in the 40 μg group and 3·1% (3·5) in 
the 20 μg group (difference 3·1%, 1·0 to 5·3, p=0·003).
At 15 months, the mean increase in spine strength was significantly higher in the 40 μg 
group (33·3% [SD 14·0]) than the 20 μg group (18·5% [9·5]; difference 14·8%, 95% CI 3·1 
to 12·0, p<0·0001), and mean total hip strength had also increased to a greater extent in the 
40 μg group (7·9% [5·3]) than the 20 μg group (4·3% [4·0]; difference 3·6%, 1·3 to 4·7, 
p=0·007)
At 3 months, median bone formation marker concentrations had increased to a greater extent 
in the 40 μg than the 20 μg group (204% vs 123% for osteocalcin; 337% vs 142% for P1NP; 
p<0·0001 for both comparisons; figure 4). At 9 months, concentrations of these markers 
were suppressed to below the original pre-treatment baseline concentrations in both groups 
and the extent of suppression was greater in the 20 μg group than the 40 μg group. At 15 
months, all markers were similarly suppressed in both groups.
30 (77%) of 39 participants in the 20 μg group and 29 (78%) of 37 participants in the 40 μg 
group had adverse events, and nine (23%) and two (5%) patients had serious adverse events 
(table 2). No participants developed hypercalcemia (measured 24 h after teriparatide 
administration). Seven patients in the 20 μg group had serious adverse events, which 
included fractures in three patients (two at the radius, one at the fibula), new diagnoses of 
malignancy in three patients (transitional cell carcinoma of the kidney diagnosed after the 3 
month visit in one patient, squamous cell carcinoma of the tongue diagnosed after the 3 
month visit in one patient, and ductal carcinoma in situ of the breast diagnosed on screening 
mammogram shortly before the 15 month visit in one patient), and shoulder dislocation, 
pancreatitis, and non-cardiac chest in a single patient. Two patients in the 40 μg group had 
serious adverse events, which included 1 week of musculoskeletal back pain that required an 
emergency room visit in one patient and a scheduled hip replacement for a congenital 
malformation in one patient. One participant in the 20 μg group discontinued within 1 month 
of enrolment due to headache. Three participants in the 40 μg group discontinued due to 
transient eczema rash, hypertension, and asthma. Specifically, the participant who had 
hypertension in the 40 μg group was diagnosed with hypertension at a routine primary care 
visit within 1 month of enrolment. The other participant in the 40 μg group chose to 
discontinue at 8 months due to a cough that led to a new diagnosis of asthma. All serious 
adverse events were considered unrelated to treatment, with the exception of headache and 
rash, as assessed by study investigators and an independent safety monitoring board. 
Additionally, one participant in the 20 μg group was withdrawn due to non-adherence; she 
presented to her 3 month visit late (after 5 months) and reported approximately 50% 
adherence due to travel commitments.
Discussion
In this 15 month randomised controlled trial, we showed that combined treatment with 
teriparatide 40 μg and denosumab increases BMD at the hip and spine to a greater extent 
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than a similar regimen with 20 μg teriparatide and denosumab. Although comparisons in 
BMD increases across different studies should be made with caution, notably, the increases 
in spine aBMD observed after 12 months of treatment with currently approved anabolic or 
antiresorptive therapies range from 4 to 14%,1–10 which is significantly lower than the 
increase in lumbar spine BMD observed with the 40 μg regimen in the current trial (17·5%). 
Similarly, at 12 months, increases in femoral neck aBMD with most currently approved 
anabolic or antiresorptive therapies range from 2 to 3% compared with an increase of 6·1% 
in total hip aBMD with the 40 μg regimen, and these increases are comparable to increases 
in total hip aBMD observed with the mixed anabolic and antiresorptive sclerostin-inhibitor, 
romosozumab.1–10 Furthermore, mean spine vBMD increased by more than 30% in the 40 
μg group, which is several times higher than that reported with other approved drugs 
(including romosozumab) after 12 months of treatment (range 4—13%). Total hip vBMD 
increased by 6·3%, which is several times higher than that reported for single drugs or 
combinations (range 1·3%).11,25–28 The increases in vBMD observed in the 40 μg group 
translated to spine and hip strength increases of more than 30% and 7%, respectively, which 
are also greater than that reported with other drugs, including oral bisphosphonates, 
denosumab, teriparatide, and romosozumab, which after treatment for 12·18 months range 
from approximately 4·27% and 2·6% at the spine and hip, respectively.20,26–32
The precise cellular and molecular mechanisms underlying the efficacy of combined 
denosumab and teriparatide cannot be completely defined in the absence of 
histomorphometric and molecular analysis of bone biopsy tissue. However, the changes in 
biochemical markers of osteoclast and osteoblast activity continue to suggest that the 
efficacy is derived from optimising the balance between bone formation and bone resorption, 
particularly as it relates to modelling-based bone formation. In the original DATA study,15,16 
the extent of bone resorption was identical in the denosumab monotherapy and combination 
groups, whereas bone formation markers were less suppressed in the combination group 
than the monotherapy group. An increase in modelling-based bone formation has been 
observed in patients who took either teriparatide and denosumab, although this increase was 
limited to the cancellous bone in patients who received denosumab.33
The findings of the current study suggest that high dose teriparatide stimulates even greater 
separation between bone resorption and formation than that of standard dose teriparatide and 
that denosumab maintains its capacity to inhibit bone resorption even in the presence of high 
dose teriparatide. Furthermore, the between-group difference in spine and hip BMD 
increases continued to increase between 9 and 15 months although both groups were 
receiving identical treatment during this period (denosumab monotherapy). This continued 
increase in BMD might be explained by mineralisation of a large amount of new 
undermineralised bone formed during high dose teriparatide therapy or the filling of an 
increased amount of remodelling space and reduction in cortical porosity during the 
denosumab-induced low bone turnover state.
The 40 μg daily dose of teriparatide used in this study is twice that of the dose approved by 
the US Food and Drug Administration. In a phase 3 trial4 in which women with osteoporosis 
received placebo, teriparatide 20 μg, or teriparatide 40 μg daily, both doses of teriparatide 
decreased vertebral and non-vertebral fracture risk compared with placebo, but fracture risk 
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did not differ between the teriparatide groups, despite greater BMD increases with 40 μg 
teriparatide than 20 μg teriparatide. Although the study was not specifically powered to 
detect difference in fracture risk reduction between teriparatide 20 μg and 40 μg, it has been 
hypothesised that the absence of greater fracture risk reduction, despite larger BMD 
increases in the 40 μg group, was due to the higher teriparatide dose stimulating greater 
cortical porosity and larger decreases in BMD in anatomical sites consisting of 
predominately cortical bone, which has been demonstrated in numerous human and animal 
studies.17,34–37 In the present study, bone resorption in both treatment groups was potently 
suppressed by the concomitantly administered denosumab and thus the results of the phase 3 
study are likely not applicable. Evidence suggests that the correlation between changes in 
BMD, particularly at the hip, correlate strongly across all osteoporosis treatments, regardless 
of underlying mechanism. Specifically, in a large pooled analysis38 of 21 osteoporosis drug 
trials including 83 395 participants, 69% and 74% of the non-vertebral anti-fracture efficacy 
was explained by the change in total hip or femoral neck BMD, respectively. The US patent 
for teriparatide will expire in August 2019, and thus potential generic preparations of 
teriparatide might make this combination regimen more affordable for patients.
In the previously reported phase 3 trial,4 more participants withdrew due to adverse events in 
the 40 μg dose group (11%) than the 20 μg (6%) or placebo (6%) groups. Although our 
study size was small, no differences in withdrawal rate due to side-effects were observed 
between the 40 μg group and 20 μg group and no difference in serum calcium concentrations 
were identified between either group at any timepoint, although concentrations were 
assessed 24 h after teriparatide injection (data not shown). The absence of observed 
hypercalcaemia might have been due to the inhibition of bone resorption (and hence calcium 
release from the bone matrix) by denosumab. Additionally, all fractures and cancer 
diagnoses were reported in the 20 μg group. Considering the sample size, conclusions 
regarding differences in safety between these two dose regimens cannot be made.
This study has some limitations. The study was done at a single site in a predominantly 
white population, which might limit the generalisability of the results. It should also be 
noted that the analysis of biochemical markers of bone turnover were only done in 
participants who completed all study visits. However, the baseline characteristics of this 
subset of women were similar to the complete study population (data not shown). 
Additionally, decreases in bone marrow fat might lead to an overestimate of increases in 
vBMD by single-energy quantitative CT and parathyroid hormone has been reported to 
reduce bone marrow fat in animal studies.39,40 The relatively small size of the study does not 
allow for direct assessment of fracture benefit nor does it allow for rigorous evaluation of the 
tolerability and safety of this treatment.
In summary, the combination of denosumab and high dose teriparatide results in large 
increases in aBMD and vBMD of the hip and spine resulting in increases in estimated bone 
strength, which has not been achieved with any previously evaluated monotherapy or 
combination therapy approaches. Considering that skeletal integrity cannot be fully restored 
in most patients with established osteoporosis at present, this 40 μg regimen is likely to 
provide benefits for women at the highest risk of fragility fracture. Direct assessment of the 
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potential of this combination to reduce the incidence of fractures compared with the current 
standard of osteoporosis care is warranted.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in context
Evidence before this study
We searched PubMed from database inception until Jan 31, 2019, using the search terms 
“anabolic”, “antiresorptive”, “osteoporosis”, and “combination therapy”, without 
language restrictions. We reviewed all randomised, controlled trials and pertinent animal 
studies published in peer-reviewed journals. Our group previously demonstrated that in 
postmenopausal women with osteoporosis, the combination of teriparatide and 
denosumab increases bone density more than either drug alone.
Added value of this study
This study shows that combined treatment with high dose teriparatide and denosumab 
increased bone mineral density at the spine and hip to a greater extent than did combined 
treatment with standard dose teriparatide and denosumab in postmenopausal women with 
osteoporosis. Furthermore, these rapid increases in bone density are larger than that 
observed with any currently available drug or other combination therapy approaches.
Implications of all the available evidence
This novel combination of high dose anabolic and antiresorptive treatment could have 
important therapeutic implications for the treatment of women at high risk of fragility 
fractures.
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Figure 1: Trial profile
ITT=intention-to-treat.
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Figure2: Mean percentage change in aBMD of the lumbar spine (A), distal radius (B), femoral 
neck (C), and total hip (D)
Error bars show standard error. For the lumbar spine and distal one-third of the radial shaft, 
patient numbers differ from the number included in the intention-to-treat population because 
dual x-ray absorptiometry was not possible at these sites in some patients. aBMD=areal 
bone mineral density. *p<0·05 for between-group comparison.
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Figure3: Mean percentage change in volumetric bone mineral density of the lumbar spine (A), 
femoral neck (B), and total hip (C) and estimated strength of the spine (D) and hip (E)
Error bars show 95% CIs. Patient numbers differ from the number included in the modified 
intention-to-treat population because quantitative CT was only done at months 0 and 15, and 
quantitative CT was not possible in some patients.
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Figure 4: Median percentage change in serum concentrations of biochemical markers
Change in biochemical markers of bone formation, osteocalcin (A) and P1NP (B), and 
biochemical marker of bone resorption CTX (C). Error bars show IQR. P1NP=N-terminal 
propeptide of type 1 procollagen. CTX=C-Terminal Telopeptide of Type I Collagen. 
*p<0·001 for between-group comparison. †p<0·05 for between-group comparison.
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Table 1:
Baseline characteristics of the modified intention-to-treat population
Denosumab plus
teriparatide 20 µg
(n=35)
Denosumab plus
teriparatide 40 µg
(n=34)
Age, years       65·9 (7·0)       67·0 (7·3)
Body-mass index, kg/m2       23·0 (2·9)       22·8 (3·9)
White, non-Hispanic       33 (94%)       33 (97%)
History of adult fragility fracture*       16 (46%)       23 (68%)
Previous bisphosphonate use       21 (60%)       19 (56%)
 Duration of use, months       45·3 (30·8)       64·5 (51·9)
 Time since discontinuation,months       72·3 (60·9)       74·7 (57·7)
Serum osteocalcin, μg/L       22·9 (5·7)       25·2 (7·6)
Serum P1NP, μg/L       49·1 (15·9)       51·5 (16·0)
Serum CTX, ng/L     426 (166)     465 (165)
Areal bone mineral density, g/cm2
 Lumbar spine    0·830 (0·104)    0·794 (0·109)
 Femoral neck    0·649 (0·092)    0·623 (0·073)
 Total hip    0·743 (0·102)    0·737 (0·074)
 Distal one-third of the radial shaft    0·604 (0·071)    0·594 (0·070)
Volumetric bone density, mg/cm2
 Lumbar spine     96·4 (27·7)     93·6 (21·6)
 Femoral neck   272·3 (39·3)   264·3 (47·9)
 Total hip   240·0 (39·8)   239·2 (30·4)
Bone strength, N†
 Lumbar spine   4862 (965)   4796 (829)
 Hip   3382 (546)   3335 (436)
Data are mean (SD) or n (%). P1NP=N-propeptide of type 1 procollagen. CTX=C-terminal telopeptide of type 1 collagen. N=Newtons.
*Adult fragility fracture defined as low trauma fracture after age 40 years.
†
Determined by finite element analysis.
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Table 2:
Adverse events
Denosumab
plus
teriparatide
20 µg (n=39)
Denosumab
plus
teriparatide
40 µg (n=37)
Any adverse event during treatment 30 (77%) 29 (78%)
Deaths   0 (0)   0 (0)
Any serious adverse event during treatment   7 (18%)   2 (5%)
Discontinuations due to adverse events   4 (10%)   2 (5%)
Adverse events occurring in >10% of patients
 Fatigue 12 (31%) 14 (38%)
 Nausea   8 (21%) 16 (43%)
 Joint pain 15 (38%) 17 (46%)
 Rhinorrhoea   8 (21%) 11 (30%)
 Dizziness   9 (23%)   8 (22%)
 Eczema   7 (18%) 11 (30%)
 Paraesthesia   9 (23%)   3 (8%)
 Muscle cramp 15 (38%) 13 (35%)
 Abnormal heart rate   6 (15%)   2 (5%)
Data are n (%).
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